Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 463

1.

Mapping the University of Washington Quality of life questionnaire onto EQ-5D and HUI-3 indices in patients with head and neck cancer.

Stephens RF, Noel CW, Su JS, Xu W, Krahn M, Monteiro E, Goldstein DP, Giuliani M, Hansen AR, de Almeida JR.

Head Neck. 2019 Nov 24. doi: 10.1002/hed.26031. [Epub ahead of print]

PMID:
31762112
2.

A model-based framework for chronic hepatitis C prevalence estimation.

Hamadeh A, Feng Z, Krahn M, Wong WWL.

PLoS One. 2019 Nov 21;14(11):e0225366. doi: 10.1371/journal.pone.0225366. eCollection 2019.

3.

Picturing ELSI+: a visual representation of ethical, legal, and social issues, and patient experiences in Health Technology Assessment in Canada.

Krahn MD, Bremner KE, de Oliveira C, Almeida N, Clement F, Lorenzetti DL, O'Campo P, Pechlivanoglou P, Tricco AC.

Int J Technol Assess Health Care. 2019 Nov 15:1-10. doi: 10.1017/S0266462319000722. [Epub ahead of print]

PMID:
31729308
4.

Estimation of fibrosis progression rates for chronic hepatitis C: a systematic review and meta-analysis update.

Erman A, Krahn MD, Hansen T, Wong J, Bielecki JM, Feld JJ, Wong WWL, Grootendorst P, Thein HH.

BMJ Open. 2019 Nov 11;9(11):e027491. doi: 10.1136/bmjopen-2018-027491.

5.

SIESTA - Home sleep study with BresoDx for obstructive sleep apnea: a randomized controlled trial.

Fitzpatrick M, Rac VE, Mitsakakis N, Abrahamyan L, Pechlivanoglou P, Chung S, Carcone SM, Pham B, Kendzerska T, Zwarenstein M, Gottschalk R, George C, Kashgari A, Krahn M.

Sleep Med. 2019 Jul 22;65:45-53. doi: 10.1016/j.sleep.2019.07.013. [Epub ahead of print]

PMID:
31707288
6.

Valuing Health State: An EQ-5D-5L Value Set for Ethiopians.

Welie AG, Gebretekle GB, Stolk E, Mukuria C, Krahn MD, Enquoselassie F, Fenta TG.

Value Health Reg Issues. 2019 Nov 1;22:7-14. doi: 10.1016/j.vhri.2019.08.475. [Epub ahead of print]

PMID:
31683254
7.

Long-term morbidity and mortality in a Canadian post-transfusion hepatitis C cohort: Over 15 years of follow-up.

Sahakyan Y, Wong WW, Yi Q, Thein HH, Tomlinson GA, Krahn MD.

J Viral Hepat. 2019 Oct 26. doi: 10.1111/jvh.13226. [Epub ahead of print]

PMID:
31654536
8.

The macro-metastasis/organ parenchyma interface (MMPI) - A hitherto unnoticed area.

Blazquez R, Sparrer D, Wendl C, Evert M, Riemenschneider MJ, Krahn MP, Erez N, Proescholdt M, Pukrop T.

Semin Cancer Biol. 2019 Oct 21. pii: S1044-579X(19)30181-6. doi: 10.1016/j.semcancer.2019.10.012. [Epub ahead of print] Review.

9.

Patterns of Care and Costs for Older Patients With Colorectal Cancer at the End of Life: Descriptive Study of the United States and Canada.

Bremner KE, Yabroff KR, Coughlan D, Liu N, Zeruto C, Warren JL, de Oliveira C, Mariotto AB, Lam C, Barrett MJ, Chan KK, Hoch JS, Krahn MD.

J Oncol Pract. 2019 Oct 24:JOP1900061. doi: 10.1200/JOP.19.00061. [Epub ahead of print]

PMID:
31647697
10.

LEF1 supports metastatic brain colonization by regulating glutathione metabolism and increasing ROS resistance in breast cancer.

Blazquez R, Rietkötter E, Wenske B, Wlochowitz D, Sparrer D, Vollmer E, Müller G, Seegerer J, Sun X, Dettmer K, Barrantes-Freer A, Stange L, Utpatel K, Bleckmann A, Treiber H, Bohnenberger H, Lenz C, Schulz M, Reimelt C, Hackl C, Grade M, Büyüktas D, Siam L, Balkenhol M, Stadelmann C, Kube D, Krahn MP, Proescholdt MA, Riemenschneider MJ, Evert M, Oefner PJ, Klein CA, Hanisch UK, Binder C, Pukrop T.

Int J Cancer. 2019 Oct 18. doi: 10.1002/ijc.32742. [Epub ahead of print]

PMID:
31626715
11.

New Insights into the Epidemiology of Prostate Cancer in Ontario.

Abrahamyan L, Huszti E, Bremner KE, Pechlivanoglou P, Mitsakakis N, Krahn M.

Cancer Invest. 2019;37(10):513-523. doi: 10.1080/07357907.2019.1682154. Epub 2019 Nov 4.

PMID:
31617759
12.

Home Dialysis Is Associated with Lower Costs and Better Survival than Other Modalities: A Population-Based Study in Ontario, Canada.

Krahn MD, Bremner KE, de Oliveira C, Dixon SN, McFarlane P, Garg AX, Mitsakakis N, Blake PG, Harvey R, Pechlivanoglou P.

Perit Dial Int. 2019 Nov-Dec;39(6):553-561. doi: 10.3747/pdi.2018.00268. Epub 2019 Oct 3.

PMID:
31582466
13.

The health impact of delaying direct-acting antiviral treatment for chronic hepatitis C: A decision-analytic approach.

Erman A, Wong WWL, Feld JJ, Grootendorst P, Krahn MD.

Liver Int. 2019 Sep 11. doi: 10.1111/liv.14247. [Epub ahead of print]

PMID:
31509639
14.

Review of Pharmacoeconomic Studies in Russian Cancer Research: An Outside View.

Djalalov S, Djalalova D, Krahn M, Matveev N, Hoch JS.

Value Health Reg Issues. 2019 Sep;19:138-144. doi: 10.1016/j.vhri.2019.04.008. Epub 2019 Aug 28.

PMID:
31472421
15.

Health Utility Book (HUB)-Cancer: Protocol for a Systematic Literature Review of Health State Utility Values in Cancer.

Zoratti MJ, Zhou T, Chan K, Levine O, Krahn M, Husereau D, Clifford T, Schunemann H, Guyatt G, Xie F.

MDM Policy Pract. 2019 Aug 13;4(2):2381468319852594. doi: 10.1177/2381468319852594. eCollection 2019 Jul-Dec.

16.

Antiviral treatment for treatment-naïve chronic hepatitis B: systematic review and network meta-analysis of randomized controlled trials.

Wong WWL, Pechivanoglou P, Wong J, Bielecki JM, Haines A, Erman A, Saeed Y, Phoon A, Tadrous M, Younis M, Rayad NZ, Rac V, Janssen HLA, Krahn MD.

Syst Rev. 2019 Aug 19;8(1):207. doi: 10.1186/s13643-019-1126-1.

17.

Embracing the science of value in health.

Krahn M, Bryan S, Lee K, Neumann PJ.

CMAJ. 2019 Jul 2;191(26):E733-E736. doi: 10.1503/cmaj.181606. No abstract available.

PMID:
31266787
18.

Using a Health Economic Framework to Prioritize Quality Indicators: An Example With Smoking Cessation in Chronic Obstructive Pulmonary Disease.

Nam A, Naimark DMJ, Stanbrook MB, Krahn MD.

MDM Policy Pract. 2019 May 27;4(1):2381468319852358. doi: 10.1177/2381468319852358. eCollection 2019 Jan-Jun.

19.

Clinical and Cost-effectiveness of a Comprehensive geriatric assessment and management for Canadian elders with Cancer-the 5C study: a study protocol for a randomised controlled phase III trial.

Puts MTE, Hsu T, Mariano C, Monette J, Brennenstuhl S, Pitters E, Ray J, Wan-Chow-Wah D, Kozlowski N, Krzyzanowska M, Amir E, Elser C, Jang R, Prica A, Krahn M, Beland F, Bergman S, Koneru R, Lemonde M, Szumacher E, Zidulka J, Fung S, Li A, Emmenegger U, Mehta R, Flemming K, Breunis H, Alibhai SMH.

BMJ Open. 2019 May 10;9(5):e024485. doi: 10.1136/bmjopen-2018-024485.

20.

Correction of pseudoexon splicing caused by a novel intronic dysferlin mutation.

Dominov JA, Uyan Ö, McKenna-Yasek D, Nallamilli BRR, Kergourlay V, Bartoli M, Levy N, Hudson J, Evangelista T, Lochmuller H, Krahn M, Rufibach L, Hegde M, Brown RH Jr.

Ann Clin Transl Neurol. 2019 Mar 3;6(4):642-654. doi: 10.1002/acn3.738. eCollection 2019 Apr.

21.

Toward a Centralized, Systematic Approach to the Identification, Appraisal, and Use of Health State Utility Values for Reimbursement Decision Making: Introducing the Health Utility Book (HUB).

Xie F, Zoratti M, Chan K, Husereau D, Krahn M, Levine O, Clifford T, Schunemann H, Guyatt G.

Med Decis Making. 2019 May;39(4):370-378. doi: 10.1177/0272989X19837969. Epub 2019 Mar 22.

PMID:
30902030
22.

Chlorhexidine-Related Mortality Rate in Critically Ill Subjects in Intensive Care Units: A Systematic Review and Meta-Analysis.

Lee S, Lighvan NL, McCredie V, Pechlivanoglou P, Krahn M, Quiñonez C, Azarpazhooh A.

Respir Care. 2019 Mar;64(3):337-349. doi: 10.4187/respcare.06434. Review.

PMID:
30850551
23.

The Effect of Cardiac Rehabilitation on Health-Related Quality of Life in Patients With Coronary Artery Disease: A Meta-analysis.

Francis T, Kabboul N, Rac V, Mitsakakis N, Pechlivanoglou P, Bielecki J, Alter D, Krahn M.

Can J Cardiol. 2019 Mar;35(3):352-364. doi: 10.1016/j.cjca.2018.11.013. Epub 2018 Nov 24. Review.

PMID:
30825955
24.

How Procurement Judges The Value of Medical Technologies: A Review of Healthcare Tenders.

Miller FA, Lehoux P, Peacock S, Rac VE, Neukomm J, Barg C, Bytautas JP, Krahn M.

Int J Technol Assess Health Care. 2019 Jan;35(1):50-55. doi: 10.1017/S0266462318003756. Epub 2019 Feb 8. Review.

PMID:
30732667
25.

Comparative effectiveness of the different components of care provided in heart failure clinics-protocol for a systematic review and network meta-analysis.

Slater M, Bielecki J, Alba AC, Abrahamyan L, Tomlinson G, Mak S, MacIver J, Zieroth S, Lee D, Wong W, Krahn M, Ross H, Rac VE.

Syst Rev. 2019 Feb 2;8(1):40. doi: 10.1186/s13643-019-0953-4.

26.

Estimating the clinical cost of drug development for orphan versus non-orphan drugs.

Jayasundara K, Hollis A, Krahn M, Mamdani M, Hoch JS, Grootendorst P.

Orphanet J Rare Dis. 2019 Jan 10;14(1):12. doi: 10.1186/s13023-018-0990-4.

27.

A phase II randomized controlled trial of three exercise delivery methods in men with prostate cancer on androgen deprivation therapy.

Alibhai SMH, Santa Mina D, Ritvo P, Tomlinson G, Sabiston C, Krahn M, Durbano S, Matthew A, Warde P, O'Neill M, Timilshina N, Segal R, Culos-Reed N.

BMC Cancer. 2019 Jan 3;19(1):2. doi: 10.1186/s12885-018-5189-5.

28.

Drosophila Sister-of-Sex-lethal reinforces a male-specific gene expression pattern by controlling Sex-lethal alternative splicing.

Moschall R, Rass M, Rossbach O, Lehmann G, Kullmann L, Eichner N, Strauss D, Meister G, Schneuwly S, Krahn MP, Medenbach J.

Nucleic Acids Res. 2019 Mar 18;47(5):2276-2288. doi: 10.1093/nar/gky1284.

29.

A National French consensus on gene lists for the diagnosis of myopathies using next-generation sequencing.

Krahn M, Biancalana V, Cerino M, Perrin A, Michel-Calemard L, Nectoux J, Leturcq F, Bouchet-Séraphin C, Acquaviva-Bourdain C, Campana-Salort E, Molon A, Urtizberea JA, Audic F, Chabrol B, Pouget J, Froissart R, Melki J, Rendu J, Petit F, Métay C, Seta N, Sternberg D, Fauré J, Cossée M.

Eur J Hum Genet. 2019 Mar;27(3):349-352. doi: 10.1038/s41431-018-0305-1. Epub 2018 Dec 14.

PMID:
30552423
30.

Comparative Effectiveness of the Core Components of Cardiac Rehabilitation on Mortality and Morbidity: A Systematic Review and Network Meta-Analysis.

Kabboul NN, Tomlinson G, Francis TA, Grace SL, Chaves G, Rac V, Daou-Kabboul T, Bielecki JM, Alter DA, Krahn M.

J Clin Med. 2018 Dec 4;7(12). pii: E514. doi: 10.3390/jcm7120514. Review.

31.

[Towards an harmonization of diagnosis by NGS of neuromuscular diseases - Actions of the Molecular Genetics sub-group of FILNEMUS].

Perrin A, Latour P, Procaccio V, Jardel C, Cérino M, Bonne G, Salort-Campana E, Urtizberea JA, Pouget J, Krahn M, Cossée M.

Med Sci (Paris). 2018 Nov;34 Hors série n°2:20-22. doi: 10.1051/medsci/201834s206. Epub 2018 Nov 12. French. No abstract available.

32.

Protocol for a phase III RCT and economic analysis of two exercise delivery methods in men with PC on ADT.

Alibhai SMH, Ritvo P, Santa Mina D, Sabiston C, Krahn M, Tomlinson G, Matthew A, Lukka H, Warde P, Durbano S, O'Neill M, Culos-Reed SN.

BMC Cancer. 2018 Oct 23;18(1):1031. doi: 10.1186/s12885-018-4937-x.

33.

Future Directions for Cost-effectiveness Analyses in Health and Medicine.

Neumann PJ, Kim DD, Trikalinos TA, Sculpher MJ, Salomon JA, Prosser LA, Owens DK, Meltzer DO, Kuntz KM, Krahn M, Feeny D, Basu A, Russell LB, Siegel JE, Ganiats TG, Sanders GD.

Med Decis Making. 2018 Oct;38(7):767-777. doi: 10.1177/0272989X18798833.

PMID:
30248277
34.

Dysferlin Exon 32 Skipping in Patient Cells.

Barthélémy F, Courrier S, Lévy N, Krahn M, Bartoli M.

Methods Mol Biol. 2018;1828:489-496. doi: 10.1007/978-1-4939-8651-4_31.

PMID:
30171562
35.

Pharmacotherapy vs surgery as initial therapy for patients with moderate-to-severe benign prostate hyperplasia: a cost-effectiveness analysis.

Erman A, Masucci L, Krahn MD, Elterman DS.

BJU Int. 2018 Nov;122(5):879-888. doi: 10.1111/bju.14520. Epub 2018 Sep 11.

36.

Resource Utilization and Costs in Adolescents Treated for Cancer in Pediatric vs Adult Institutions.

Nathan PC, Bremner KE, Liu N, Gupta S, Greenberg ML, McBride ML, Krahn MD, de Oliveira C.

J Natl Cancer Inst. 2019 Mar 1;111(3):322-330. doi: 10.1093/jnci/djy119.

37.

Getting a Notch closer to renal dysfunction: activated Notch suppresses expression of the adaptor protein Disabled-2 in tubular epithelial cells.

Schütte-Nütgen K, Edeling M, Mendl G, Krahn MP, Edemir B, Weide T, Kremerskothen J, Michgehl U, Pavenstädt H.

FASEB J. 2019 Jan;33(1):821-832. doi: 10.1096/fj.201800392RR. Epub 2018 Jul 27.

PMID:
30052485
38.

DEVELOPMENT OF THE ONTARIO DECISION FRAMEWORK: A VALUES BASED FRAMEWORK FOR HEALTH TECHNOLOGY ASSESSMENT.

Krahn M, Miller F, Bayoumi A, Brooker AS, Wagner F, Winsor S, Giacomini M, Goeree R, Schünemann H, van der Velde G, Petersen S, Sikich N, Dhalla I.

Int J Technol Assess Health Care. 2018 Jun;34(3):290-299. doi: 10.1017/S0266462318000235.

PMID:
29987995
39.

Cost analysis of Greenlight photoselective vaporization of the prostate compared to transurethral resection of the prostate for benign prostatic hyperplasia.

Masucci L, Erman A, Krahn MD, Elterman D.

Can Urol Assoc J. 2018 Jun 19. doi: 10.5489/cuaj.5267. [Epub ahead of print]

40.

The lifetime cost of spinal cord injury in Ontario, Canada: A population-based study from the perspective of the public health care payer.

Chan BC, Cadarette SM, Wodchis WP, Krahn MD, Mittmann N.

J Spinal Cord Med. 2019 Mar;42(2):184-193. doi: 10.1080/10790268.2018.1486622. Epub 2018 Jun 20.

PMID:
29923798
41.

Imaging in Biologically-Relevant Environments with AFM Using Stiff qPlus Sensors.

Pürckhauer K, Weymouth AJ, Pfeffer K, Kullmann L, Mulvihill E, Krahn MP, Müller DJ, Giessibl FJ.

Sci Rep. 2018 Jun 19;8(1):9330. doi: 10.1038/s41598-018-27608-6.

42.

VarAFT: a variant annotation and filtration system for human next generation sequencing data.

Desvignes JP, Bartoli M, Delague V, Krahn M, Miltgen M, Béroud C, Salgado D.

Nucleic Acids Res. 2018 Jul 2;46(W1):W545-W553. doi: 10.1093/nar/gky471.

43.

Carpal Tunnel Syndrome Management in Breast Cancer Survivors at Risk for Lymphedema: A Markov Model.

Retrouvey H, Krahn M, Baltzer HL.

Plast Reconstr Surg. 2018 May;141(5):689e-696e. doi: 10.1097/PRS.0000000000004318.

PMID:
29697616
44.

MoBiDiC Prioritization Algorithm, a Free, Accessible, and Efficient Pipeline for Single-Nucleotide Variant Annotation and Prioritization for Next-Generation Sequencing Routine Molecular Diagnosis.

Yauy K, Baux D, Pegeot H, Van Goethem C, Mathieu C, Guignard T, Juntas Morales R, Lacourt D, Krahn M, Lehtokari VL, Bonne G, Tuffery-Giraud S, Koenig M, Cossée M.

J Mol Diagn. 2018 Jul;20(4):465-473. doi: 10.1016/j.jmoldx.2018.03.009. Epub 2018 Apr 22.

PMID:
29689380
45.

Turning High-Risk Individuals: An Economic Evaluation of Repositioning Frequency in Long-Term Care.

Pechlivanoglou P, Paulden M, Pham B, Wong J, Horn SD, Krahn M.

J Am Geriatr Soc. 2018 Jul;66(7):1409-1414. doi: 10.1111/jgs.15387. Epub 2018 Apr 20.

46.

Controlling the master-upstream regulation of the tumor suppressor LKB1.

Kullmann L, Krahn MP.

Oncogene. 2018 Jun;37(23):3045-3057. doi: 10.1038/s41388-018-0145-z. Epub 2018 Mar 15. Review.

PMID:
29540834
47.

The Bladder Utility Symptom Scale: A Novel Patient Reported Outcome Instrument for Bladder Cancer.

Perlis N, Krahn MD, Boehme KE, Alibhai SMH, Jamal M, Finelli A, Sridhar SS, Chung P, Gandhi R, Jones J, Tomlinson G, Bremner KE, Kulkarni G.

J Urol. 2018 Aug;200(2):283-291. doi: 10.1016/j.juro.2018.03.006. Epub 2018 Mar 9.

PMID:
29530786
48.

Redundant regulation of localization and protein stability of DmPar3.

Kullmann L, Krahn MP.

Cell Mol Life Sci. 2018 Sep;75(17):3269-3282. doi: 10.1007/s00018-018-2792-1. Epub 2018 Mar 10.

PMID:
29523893
49.

Muscle Cells Fix Breaches by Orchestrating a Membrane Repair Ballet.

Barthélémy F, Defour A, Lévy N, Krahn M, Bartoli M.

J Neuromuscul Dis. 2018;5(1):21-28. doi: 10.3233/JND-170251. Review.

50.

Differences in Incremental Cost-Effectiveness Ratios for Common Versus Rare Conditions: A Case from Oncology.

Jayasundara K, Krahn M, Mamdani M, Hoch JS, Grootendorst P.

Pharmacoecon Open. 2017 Sep;1(3):167-173. doi: 10.1007/s41669-017-0022-7.

Supplemental Content

Support Center